Patent foramen ovale closure and medical treatments for secondary stroke prevention: A systematic review of observational and randomized evidence

Stroke

Volumn 43, Issue 2, 2012, Pages 422-431

  Kitsios, Georgios D ^a,b,c   Dahabreh, Issa J ^a   Dabrh, Abd Moain Abu ^a   Thaler, David E ^a,c   Kent, David M ^a,c  

^a TUFTS MEDICAL CENTER   (United States)

^b LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

meta analysis; observational studies; patent foramen ovale; stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; PATENT FORAMEN OVALE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; STROKE;

ADULT; AGE FACTORS; AGED; ANTICOAGULANTS; BIAS (EPIDEMIOLOGY); CEREBROVASCULAR DISORDERS; DATA INTERPRETATION, STATISTICAL; FEMALE; FORAMEN OVALE, PATENT; HUMANS; ISCHEMIC ATTACK, TRANSIENT; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROSURGICAL PROCEDURES; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REPRODUCIBILITY OF RESULTS; SECONDARY PREVENTION; SEX FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84856440512     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.631648     Document Type: Article

References (84)

1. Khairy P, O'Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: A systematic review. Ann Intern Med. 2003;139: 753-760. (Pubitemid 38129075)
2. Homma S, Sacco RL. Patent foramen ovale and stroke. Circulation. 2005;112:1063-1072.
3. Wohrle J. Closure of patent foramen ovale after cryptogenic stroke. Lancet. 2006;368:350-352.
4. Holzer R, Hijazi Z. The off-versus on-label use of medical devices in interventional cardiovascular medicine?: Clarifying the ambiguity between regulatory labeling and clinical decision making, part III: structural heart disease interventions. Catheter Cardiovasc Interv. 2008; 72:848-852.
5. Furlan AJ. A prospective, multicenter, randomized controlled trial to evaluate the safety and efficacy of the STARFlex septal closure system versus best medical therapy in patients with a stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale. Available at: http://www.crtonline.org/flash.aspx?PAGE-Id 7730. Accessed October 18, 2011.
6. Landzberg MJ, Khairy P. Indications for the closure of patent foramen ovale. Heart. 2004;90:219-224. (Pubitemid 38147168)
7. Almekhlafi MA, Wilton SB, Rabi DM, Ghali WA, Lorenzetti DL, Hill MD. Recurrent cerebral ischemia in medically treated patent foramen ovale: A meta-analysis. Neurology. 2009;73:89-97.
8. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
9. Jüni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 1999;282:1054-1060. (Pubitemid 29436453)
10. Bagos P, Nikolopoulos GK. Mixed-Effects Poisson Regression Models for Meta-Analysis of Follow-Up Studies with Constant or Varying Durations. Int J Biostat. 2009;5:Article 21.
11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188. (Pubitemid 17189972)
12. Begg CB, Pilote L. A model for incorporating historical controls into a meta-analysis. Biometrics. 1991;47:899-906.
13. Brumback BA, Holmes LB, Ryan LM. Adverse effects of chorionic villus sampling: A meta-analysis. Stat Med. 1999;18:2163-2175. (Pubitemid 29408258)
14. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med. 2002;21:589-624. (Pubitemid 34141379)
15. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21:1559-1573. (Pubitemid 34746063)
16. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219. (Pubitemid 36143396)
17. Wallace BC, Schmid CH, Lau J, Trikalinos TA. Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol. 2009;9:80.
18. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43-46. (Pubitemid 20255621)
19. van de Wyngaert F, Kefer J, Hermans C, Ovaert C, Pasquet A, Beguin C, et al. Absence of recurrent stroke after percutaneous closure of patent foramen ovale despite residual right-to-left cardiac shunt assessed by transcranial Doppler. Arch Cardiovasc Dis. 2008;101:435-441.
20. Wahl A, Praz F, Tai T, Findling O, Walpoth N, Nedeltchev K, et al. Improvement of migraine headaches after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism. Heart. 2010;96:967-973.
21. Zhang CJ, Huang YG, Huang XS, Huang T, Huang WH, Shen JJ, et al. Transcatheter closure of patent foramen ovale with the Spider patent foramen ovale occluder: A prospective, single-center trial. Chin Med J (Engl). 2010;123:834-837.
22. Casaubon L, McLaughlin P, Webb G, Yeo E, Merker D, Jaigobin C. Recurrent stroke/TIA in cryptogenic stroke patients with patent foramen ovale. Can J Neurol Sci. 2007;34:74-80. (Pubitemid 46423346)
23. Cerrato P, Priano L, Imperiale D, Bosco G, Destefanis E, Villar AM, et al. Recurrent cerebrovascular ischaemic events in patients with interatrial septal abnormalities: A follow-up study. Neurol Sci. 2006;26:411-418.
24. Harrer JU, Wessels T, Franke A, Lucas S, Berlit P, Klotzsch C. Stroke recurrence and its prevention in patients with patent foramen ovale. Can J Neurol Sci. 2006;33:39-47.
25. Schuchlenz HW, Weihs W, Berghold A, Lechner A, Schmidt R. Secondary prevention after cryptogenic cerebrovascular events in patients with patent foramen ovale. Int J Cardiol. 2005;101:77-82. (Pubitemid 40614739)
26. Thanopoulos BV, Dardas PD, Karanasios E, Mezilis N. Transcatheter closure versus medical therapy of patent foramen ovale and cryptogenic stroke. Catheter Cardiovasc Interv. 2006;68:741-746. (Pubitemid 44721098)
27. Weimar C, Holle DN, Benemann J, Schmid E, Schminke U, Haberl RL, et al. Current management and risk of recurrent stroke in cerebrovascular patients with right-to-left cardiac shunt. Cerebrovasc Dis. 2009;28: 349-356.
28. Windecker S, Wahl A, Nedeltchev K, Arnold M, Schwerzmann M, Seiler C, et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J Am Coll Cardiol. 2004;44:750-758.
29. Anzola GP, Zavarize P, Morandi E, Rozzini L, Parrinello G. Transcranial Doppler and risk of recurrence in patients with stroke and patent foramen ovale. Eur J Neurol. 2003;10:129-135. (Pubitemid 36308206)
30. Anzola GP, Morandi E, Casilli F, Onorato E. Does transcatheter closure of patent foramen ovale really "shut the door?" A prospective study with transcranial Doppler. Stroke. 2004;35:2140-2144. (Pubitemid 39129575)
31. Aslam F, Iliadis AE, Blankenship JC. Percutaneous closure of patent foramen ovale: success and outcomes of a low-volume procedure at a rural medical center. J Invasive Cardiol. 2007;19:20-24. (Pubitemid 46091517)
32. Papa M, Gaspardone A, Fragasso G, Ajello S, Gioffre G, Iamele M, et al. Usefulness of transcatheter patent foramen ovale closure in migraineurs with moderate to large right-to-left shunt and instrumental evidence of cerebrovascular damage. Am J Cardiol. 2009;104:434-439.
33. Shafi NA, McKay RG, Kiernan FJ, Silverman IE, Ahlquist M, Silverman DI. Determinants and clinical significance of persistent residual shunting in patients with percutaneous patent foramen ovale closure devices. Int J Cardiol. 2009;137:314-316.
34. Spies C, Khandelwal A, Timmemanns I, Kavinsky CJ, Schrader R, Hijazi ZM. Recurrent events following patent foramen ovale closure in patients above 55 years of age with presumed paradoxical embolism. Catheter Cardiovasc Interv. 2008;72:966-970.
35. von Bardeleben RS, Richter C, Otto J, Himmrich L, Schnabel R, Kampmann C, et al. Long term follow up after percutaneous closure of PFO in 357 patients with paradoxical embolism: Difference in occlusion systems and influence of atrial septum aneurysm. Int J Cardiol. 2009; 134:33-41.
36. Balbi M, Casalino L, Gnecco G, Bezante GP, Pongiglione G, Marasini M, et al. Percutaneous closure of patent foramen ovale in patients with presumed paradoxical embolism: periprocedural results and midterm risk of recurrent neurologic events. Am Heart J. 2008;156:356-360.
37. Beitzke A, Schuchlenz H, Gamillscheg A, Stein JI, Wendelin G. Catheter closure of the persistent foramen ovale: mid-term results in 162 patients. J Interv Cardiol. 2001;14:223-229.
38. Bogousslavsky J, Garazi S, Jeanrenaud X, Aebischer N, Van Melle G. Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Lausanne Stroke with Paradoxal Embolism Study Group. Neurology. 1996;46:1301-1305. (Pubitemid 26159291)
39. Braun M, Gliech V, Boscheri A, Schoen S, Gahn G, Reichmann H, et al. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occluder systems. Eur Heart J. 2004;25: 424-430. (Pubitemid 38391525)
40. Butera G, Bini MR, Chessa M, Bedogni F, Onofri M, Carminati M. Transcatheter closure of patent foramen ovale in patients with cryptogenic stroke. Ital Heart J. 2001;2:115-118. (Pubitemid 32303446)
41. Chatterjee T, Petzsch M, Ince H, Rehders TC, Korber T, Weber F, et al. Interventional closure with Amplatzer PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism. J Interv Cardiol. 2005;18:173-179. (Pubitemid 40942728)
42. Cujec B, Mainra R, Johnson DH. Prevention of recurrent cerebral ischemic events in patients with patent foramen ovale and cryptogenic strokes or transient ischemic attacks. Can J Cardiol. 1999;15:57-64. (Pubitemid 29080518)
43. De Castro S, Cartoni D, Fiorelli M, Rasura M, Anzini A, Zanette EM, et al. Morphological and functional characteristics of patent foramen ovale and their embolic implications. Stroke. 2000;31:2407-2413.
44. Demkow M, Ruzyllo W, Kepka C, Pruszczyk P, Opuchlik A, Szyluk B, et al. Transcatheter closure of patent foramen ovale in patients with cryptogenic stroke. Kardiol Pol. 2004;61:101-109. (Pubitemid 39128176)
45. Du ZD, Cao QL, Joseph A, Koenig P, Heischmidt M, Waight DJ, et al. Transcatheter closure of patent foramen ovale in patients with paradoxical embolism: intermediate-term risk of recurrent neurological events. Catheter Cardiovasc Interv. 2002;55:189-194. (Pubitemid 34127378)
46. Dubiel M, Bruch L, Liebner M, Schmehl I, Winkelmann A, Rux S, et al. Exclusion of patients with arteriosclerosis reduces long-term recurrence rate of presumed arterial embolism after PFO closure. J Interv Cardiol. 2007;20:275-281. (Pubitemid 47228552)
47. Mazuelos F, Suarez de Lezo J, Pan M, Mesa D, Delgado M, Ruiz M, et al. [Percutaneous closure of patent foramen ovale in young patients with cryptogenic stroke: long-term follow-up]. Rev Esp Cardiol. 2008;61: 640-643. (Pubitemid 351930575)
48. Kutty S, Brown K, Asnes JD, Rhodes JF, Latson LA. Causes of recurrent focal neurologic events after transcatheter closure of patent foramen ovale with the CardioSEAL septal occluder. Am J Cardiol. 2008;101: 1487-1492.
49. Vigna C, Inchingolo V, Giannatempo G, Pacilli MA, Di VP, Fusilli S, et al. Clinical and brain magnetic resonance imaging follow-up after percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. Am J Cardiol. 2008;101:1051-1055.
50. Fischer D, Fuchs M, Schaefer A, Schieffer B, Jategaonkar S, Hornig B, et al. Transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Procedural and follow-up results after implantation of the Starflex occluder device with conjunctive intensified anticoagulation regimen. J Interv Cardiol. 2008;21:183-189. (Pubitemid 351490137)
51. Spies C, Timmermanns I, Reissmann U, van Essen J, Schrader R. Patent foramen ovale closure with the Intrasept occluder: Complete 6-56 months follow-up of 247 patients after presumed paradoxical embolism. Catheter Cardiovasc Interv. 2008;71:390-395.
52. Zanchetta M, Pedon L, Olivieri A, Benacchio L. Randomized study comparing mechanical with electronic 2-dimensional intracardiac ultrasound monitoring (MEDIUM) during percutaneous closure of patent foramen ovale in adult patients with cryptogenic stroke. Echocardiography. 2008;25: 496-503. (Pubitemid 351623847)
53. Egred M, Andron M, Albouaini K, Alahmar A, Grainger R, Morrison WL. Percutaneous closure of patent foramen ovale and atrial septal defect: procedure outcome and medium-term follow-up. J Interv Cardiol. 2007;20:395-401. (Pubitemid 47429143)
54. Ende DJ, Chopra PS, Rao PS. Transcatheter closure of atrial septal defect or patent foramen ovale with the buttoned device for prevention of recurrence of paradoxic embolism. Am J Cardiol. 1996;78:233-236. (Pubitemid 26244379)
55. Giardini A, Donti A, Formigari R, Salomone L, Palareti G, Guidetti D, et al. Long-term efficacy of transcatheter patent foramen ovale closure on migraine headache with aura and recurrent stroke. Catheter Cardiovasc Interv. 2006;67:625-629.
56. Hanna JP, Sun JP, Furlan AJ, Stewart WJ, Sila CA, Tan M. Patent foramen ovale and brain infarct. Echocardiographic predictors, recurrence, and prevention. Stroke. 1994;25:782-786. (Pubitemid 24111323)
57. Harms V, Reisman M, Fuller CJ, Spencer MP, Olsen JV, Krabill KA, et al. Outcomes after transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Am J Cardiol. 2007;99:1312-1315. (Pubitemid 46659874)
58. Hausmann D, Mugge A, Daniel WG. Identification of patent foramen ovale permitting paradoxic embolism. J Am Coll Cardiol. 1995;26: 1030-1038.
59. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP, PFO in Cryptogenic Stroke Study (PICSS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation. 2002;105:2625-2631. (Pubitemid 34596039)
60. Hong TE, Thaler D, Brorson J, Heitschmidt M, Hijazi ZM, Amplatzer PFO Investigators. Transcatheter closure of patent foramen ovale associated with paradoxical embolism using the amplatzer PFO occluder: initial and intermediate-term results of the U.S. multicenter clinical trial. Catheter Cardiovasc Interv. 2003;60:524-528. (Pubitemid 37466763)
61. Hung J, Landzberg MJ, Jenkins KJ, King ME, Lock JE, Palacios IF, et al. Closure of patent foramen ovale for paradoxical emboli: intermediate-term risk of recurrent neurological events following transcatheter device placement. J Am Coll Cardiol. 2000;35:1311-1316. (Pubitemid 30206906)
62. Kiblawi FM, Sommer RJ, Levchuck SG. Transcatheter closure of patent foramen ovale in older adults. Catheter Cardiovasc Interv. 2006;68: 136-142. (Pubitemid 44024476)
63. Knebel F, Gliech V, Walde T, Panda A, Sanad W, Eddicks S, et al. Percutaneous closure of interatrial communications in adults-prospective embolism prevention study with two-and three-dimensional echocardiography. Cardiovasc Ultrasound. 2004;2:5.
64. Martin F, Sanchez PL, Doherty E, Colon-Hernandez PJ, Delgado G, Inglessis I, et al. Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Circulation. 2002;106: 1121-1126. (Pubitemid 34970854)
65. Mas JL, Zuber M. Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischemic attack. French Study Group on Patent Foramen Ovale and Atrial Septal Aneurysm. Am Heart J. 1995;130: 1083-1088.
66. Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med. 2001;345:1740-1746.
67. Onorato E, Melzi G, Casilli F, Pedon L, Rigatelli G, Carrozza A, et al. Patent foramen ovale with paradoxical embolism: mid-term results of transcatheter closure in 256 patients. J Interv Cardiol. 2003;16:43-50. (Pubitemid 36293093)
68. Post MC, Van Deyk K, Budts W. Percutaneous closure of a patent foramen ovale: single-centre experience using different types of devices and mid-term outcome. Acta Cardiol. 2005;60:515-519. (Pubitemid 41433658)
69. Presbitero P, Lanzone AM, Albiero R, Lisignoli V, Zavalloni PD, Gasparini GL, et al. Anatomical patterns of patent foramen ovale (PFO): do they matter for percutaneous closure? Minerva Cardioangiol. 2009;57:275-284.
70. Rigatelli G, Dell'Avvocata F, Giordan M, Ronco F, Braggion G, Schenal N, et al. Transcatheter patent foramen ovale closure in spite of interatrial septum hypertrophy or lipomatosis: A case series. J Cardiovasc Med (Hagerstown). 2010;11:91-95.
71. Serena J, Marti-Fabregas J, Santamarina E, Rodriguez JJ, Perez-Ayuso MJ, Masjuan J, et al. Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study. Stroke. 2008;39:3131-3136.
72. Sievert H, Horvath K, Zadan E, Krumsdorf U, Fach A, Merle H, et al. Patent foramen ovale closure in patients with transient ischemia attack/stroke. J Interv Cardiol. 2001;14:261-266. (Pubitemid 32411389)
73. Slavin L, Tobis JM, Rangarajan K, Dao C, Krivokapich J, Liebeskind DS. Five-year experience with percutaneous closure of patent foramen ovale. Am J Cardiol. 2007;99:1316-1320. (Pubitemid 46659873)
74. Varma C, Benson LN, Warr MR, Yeo E, Yip J, Jaigobin CS, et al. Clinical outcomes of patent foramen ovale closure for paradoxical emboli without echocardiographic guidance. Catheter Cardiovasc Interv. 2004; 62:519-525. (Pubitemid 39045299)
75. Wahl A, Kunz M, Moschovitis A, Nageh T, Schwerzmann M, Seiler C, et al. Long-term results after fluoroscopy-guided closure of patent foramen ovale for secondary prevention of paradoxical embolism. Heart. 2008;94:336-341. (Pubitemid 351303426)
76. Dahabreh IJ, Kent DM. Index event bias as an explanation for the paradoxes of recurrence risk research. JAMA. 2011;305:822-823.
77. Concato J, Lawler EV, Lew RA, Gaziano JM, Aslan M, Huang GD. Observational methods in comparative effectiveness research. Am J Med. 2010;123(12 Suppl 1):e16-e23.
78. Berlin JA, Santanna J, Schmid CH, Szczech LA, Feldman HI. Individual patient-versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Stat Med. 2002;21:371-387. (Pubitemid 34144648)
79. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167:492-499.
80. Alsheikh-Ali AA, Thaler DE, Kent DM. Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke. 2009;40:2349-2355.
81. Kent DM, Thaler DE. Is patent foramen ovale a modifiable risk factor for stroke recurrence? Stroke. 2010;41(Suppl 10):S26-S30.
82. Benbassat J, Baumal R. Variability in duration of follow up may bias the conclusions of cohort studies of patients with patent foramen ovale. Eur J Neurol. 2008;15:909-915.
83. Tirschwell DL, Book DS, Lutsep HL, Pettigrew LC, Saver JL, Smalling RW, et al. Antiplatelet vs. Anticoagulant Therapy Recommended as Best Medical Care in the Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT) Trial. Stroke. 2010;41:e291.
84. Owens DK, Lohr KN, Atkins D, Treadwell JR, Reston JT, Bass EB, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions-Agency for Healthcare Research and Quality and the Effective Healthcare Program. J Clin Epidemiol. 2010; 63:513-523.